regorafenib + PD-1 antibody

regorafenib + PD-1 antibody is an investigational combination therapy being evaluated by Sun Yat-sen University for the treatment of metastatic colorectal cancer, particularly in patients with microsatellite stable (MSS) or mismatch repair proficient (pMMR) tumors. This regimen combines regorafenib, a small-molecule multi-kinase inhibitor that targets pathways involved in angiogenesis (VEGFR1-3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), and the tumor microenvironment (PDGFR, FGFR, CSF1R), with a PD-1 checkpoint inhibitor. The PD-1 antibody component (such as nivolumab or toripalimab) blocks the interaction between the PD-1 receptor on T cells and its ligands, thereby enhancing the immune system's ability to identify and destroy cancer cells. Clinical trials at Sun Yat-sen University have also explored the addition of radiotherapy to this combination to potentially synergize with the immunotherapy and improve objective response rates in previously treated patients.

Other names

regorafenib and PD-1 antibodyregorafenib plus PD-1 inhibitorREGONIVO